Get notified when SILO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRisk Profile Improvements
- Material Weakness (removed) — Prior filing disclosed ongoing material weakness in internal controls (lack of segregation of duties, inadequate system/manual controls); current filing states controls are effective as of December 31, 2025.
Silo Pharma pivots to crypto treasury, delays lead drug IND, terminates key MS license
Filed March 27, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 28, 2025 · ~2 min read
Key Changes
-
high
Company launched cryptocurrency treasury strategy in August 2025, deploying $320K into Bitcoin, Ethereum, Solana, and staked tokens. Management now describes the firm as a 'developmental stage biopharmaceutical and cryptocurrency company.'
Business: Cryptocurrency Treasury Strategy verify on EDGAR → -
high
Terminated exclusive UMB license for SPU-16 (multiple sclerosis peptide therapy) and replaced it with a non-renewable option expiring March 31, 2026. Company states it does not intend to extend the option.
Business: UMB License Termination verify on EDGAR → -
high
IND submission for lead PTSD candidate SPC-15 pushed from 2025 to 2026, representing a one-year delay in the regulatory timeline despite completing first GLP tox dosing in March 2025.
MD&A: SPC-15 Timeline verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PXED 10-Q) is open in full — no account needed.
Partner
Trade SILO commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify